表皮生长因子受体
医学
表皮生长因子受体抑制剂
癌症研究
癌症
转移
肺癌
血管生成
表皮生长因子
吉非替尼
西妥昔单抗
肿瘤科
内科学
受体
结直肠癌
作者
Kunyu Shi,Guan Wang,Junping Pei,Jian Zhang,Jiaxing Wang,Liang Ouyang,Yang Wang,Weimin Li
标识
DOI:10.1186/s13045-022-01311-6
摘要
Abstract Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related to the inhibition of tumor cell proliferation, angiogenesis, invasion, metastasis, and apoptosis. Therefore, EGFR has become an important target for the treatment of cancer, including non-small cell lung cancer, head and neck cancer, breast cancer, glioma, cervical cancer, and bladder cancer. First- to third-generation EGFR inhibitors have shown considerable efficacy and have significantly improved disease prognosis. However, most patients develop drug resistance after treatment. The challenge of overcoming intrinsic and acquired resistance in primary and recurrent cancer mediated by EGFR mutations is thus driving the search for alternative strategies in the design of new therapeutic agents. In view of resistance to third-generation inhibitors, understanding the intricate mechanisms of resistance will offer insight for the development of more advanced targeted therapies. In this review, we discuss the molecular mechanisms of resistance to third-generation EGFR inhibitors and review recent strategies for overcoming resistance, new challenges, and future development directions.
科研通智能强力驱动
Strongly Powered by AbleSci AI